Hemophilia Treatment Market Trends

Global Hemophilia Treatment Market Overview

Hemophilia Treatment Market Size was valued at USD 11.7 billion in 2023 and is projected to grow from USD 12.4 Billion in 2024 to USD 17.3 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.25% during the forecast period (2024 - 2032). The availability of limited treatment options and the increasing burden of regulatory agencies for their treatment have resulted in increased research and development efforts. Additionally, the government plans to conduct awareness campaigns and support initiatives to start early screening of newborns are expected to boost the demand for hemophilia-related diagnostic tools. These are the key market drivers enhancing market growth.

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Pfizer Inc. declared in May 2023 that the critical Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab had achieved its primary endpoints; the observed effects of the trial are clinically significant and statistically significant. In the trial, marstacimab, an anti-tissue factor pathway inhibitor (anti-TFPI) that is novel and being studied for the treatment of hemophilia A or B in patients devoid of Factor VIII (FVIII) or Factor IX (FIX) inhibitors, was administered subcutaneously loading dose of 300 mg once weekly, irrespective of body weight. The results of this research offer support for the notion that marstacimab may function as an initial non-factor treatment option once per week for patients diagnosed with hemophilia B. Moreover, it assists in catering to the diverse needs of patients who have hemophilia A or B but do not necessitate inhibitory agents. The prevention of excessive or potentially catastrophic hemorrhages and the reduction of treatment burden via weekly subcutaneous administration are included in these requirements.

The FDA approved Roctavian, a gene therapy for hemophilia A, developed by BioMarin, in June 2023. It is not expected that even delivering the medication to the patients will be a rapid process. The initial one-time treatment to be granted FDA approval in this therapeutic category, Roctavian (formerly BMN270), was prescribed to patients aged 18 and above who presented with the severe form of the inherited bleeding disorder. According to Biologic's estimation, around 2,500 out of the 6,500 adult patients in the United States meet the eligibility criteria for the medication. Through the administration of functional factor VIII DNA to liver cells, Roctavian has the capacity to substitute a deficient blood-clotting protein and thereby eliminate the need for continuous treatment for a minimum of five years. In Phase 3 clinical trials, the infusion drug decreased the mean annualized factor VIII infusion rate by 99% and the mean annualized hemorrhage rate by 84%.

Hemophilia Treatment Market Trends

• The rising case of bleeding disorders is boosting the market growth

The Hemophilia Treatment Market is expected to grow significantly due to the rising incidence of hemophilia or bleeding disorders. Hence, the increasing prevalence of hemophilia is expected to drive demand for hemophilia treatment in the forecast period. Furthermore, there is an increasing need for effective therapies for treating Factor VIll Insufficiency in emerging economies such as India, which is expected to drive market growth over the forecast period.

The diversity of therapies and drugs increases the demand for the market growth of the hemophilia treatment. Inhibitor therapy, home remedies, free factor replacement therapy, antifibrinolytic drugs, gene therapy, and physical therapy are some treatments and medications commonly used to treat hemophilia. These factors have had a substantial positive impact on the market growth of the hemophilia treatment.

Growing government programs and aggressive election campaigns have boosted the market growth of the hemophilia treatment in recent years. Treatment and facilities related to hemophilia treatment have been strengthened in recent years, especially in line with medical guidelines for COVID vaccination. In recent years, injectable drug delivery has grown by more than 5% due to improvements in the quality of life of hemophiliac patients and the strengthening of an overall treatment. Therefore, the market CAGR of Hemophilia Treatment has been increasing globally in recent years. These are essential factors driving the growth of the Hemophilia Treatment market revenue.

Hemophilia Treatment Market Segment Insights

Hemophilia Treatment Type Insights

Based on type, the Market segments of Hemophilia Treatment includes Hemophilia A, Hemophilia B, and Hemophilia C. The Hemophilia A segment held the majority share 2022 of the Hemophilia Treatment Market revenue. Type A is generally considered the most common type and is four times more common than type B hemophilia. According to statistics published by WebMD LLC in 2019, the prevalence of type A varies in different countries, ranging from 5.4-14.5 cases per 100,000 males. In addition, about 50-60% of patients have severe hemophilia A, all accompanied by severe bleeding. Also, most of the products available are used to treat hemophilia A.

Figure 1: Hemophilia Treatment Market by Type, 2021 & 2030 (USD Million)Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Hemophilia Treatment End-Use Insights

Based on end-use, the global Hemophilia Treatment industry has been segmented into hospital pharmacies, retail pharmacy, and others. The hospital segment is attributed to board certification opportunities for skilled hematologists, the importance of delivering quality care plans, and the efficiencies they increase. These medical facilities offer affordable treatment procedures that help patients and insurance companies. The easy availability of new treatments has surged hospital preferences for bleeding disorder treatment. Also, comprehensive hospital-provided care plans and continuous monitoring are expected to increase patient preference for these drug healthcare facilities. As a result, more and more people are being admitted to the hospital for this inherited bleeding disorder. The need for advanced treatment is expected to drive product adoption in these facilities.

Hemophilia Treatment Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Hemophilia Treatment market accounted for USD 5.1 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. Rising prevalence coupled with an increasing propensity for preventive treatment is expected to be the initial driver of regional growth. In the United States, people are diagnosed with the disease at a very young age.

Further, the significant countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: HEMOPHILIA TREATMENT MARKET SHARE BY REGION 2022 (%)Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe's Hemophilia Treatment market accounts for the second-largest market share. This is attributed to the booming research activity in hemophilia treatment in Europe due to well-established medical facilities, recent technological advancements, and increased demand for early diagnosis of hemophilia due to rising awareness about the disease. Further, the Germany market of Hemophilia Treatment held the largest market share, and the U.K. market of Hemophilia Treatment was the fastest-growing market in the European Region.

The Asia-Pacific Hemophilia Treatment Market is expected to grow at the fastest CAGR from 2022 to 2030. Asia Pacific is the fastest-growing Region in the market of Hemophilia Treatment, owing to factors such as rising R&D investment in new products for hemophilia treatment, an increasing number of hemophilia patients, and technological advancements driving the market. Moreover, the China market of Hemophilia Treatment held the largest market share, and the India market of Hemophilia Treatment was the fastest-growing market in the Asia-Pacific region.

Hemophilia Treatment Key Market Players & Competitive Insights

Major market players are spending a lot on R&D to increase their Type lines, which will help the market of Hemophilia Treatment grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new Type launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Hemophilia Treatment industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Manufacturing locally to reduce operating costs is one of the primary business strategies manufacturers adopt in the global Hemophilia Treatment industry to benefit clients and expand the market sector. The Hemophilia Treatment industry has provided medicine with some of the most significant benefits in recent years. In the Hemophilia Treatment markets, major players such as Medtronic Inc (Ireland), Abbott Laboratories (U.S.), Stryker Corporation (U.S.), and others are working on expanding the market demand by investing in research and development activities.

CSL Behring is a biopharmaceutical company that manufactures plasma-derived and recombinant therapeutic products. Its therapies include products for treating bleeding disorders such as hemophilia; hereditary angioedema; hereditary respiratory disorders; and neurological disorders. In May 2021, CSL Behring announced the completion of a commercialization and licensing agreement with uniQure for etranacogene dezaparvovec (AMT-061) to treat hemophilia B. The drug candidate is being developed by uniQure and undergoing Phase III clinical studies.

Also, Bayer AG is a German multinational pharmaceutical and biotechnology company and one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's business areas include pharmaceuticals, consumer healthcare, agrochemicals, seeds, and biotechnology products.

Key Companies in the market of Hemophilia Treatment include

• Hoffmann-La Roche Ltd


• Octapharma


• CSL Behring


• Sanofi


• Bayer AG


• Baxter


• Swedish Orphan Biovitrum AB


• Grifols International S.A


• Kedrion


• Shire, among others

Hemophilia Treatment Industry Developments

July 2021: BioMarin Pharmaceutical Inc announced that the European Medicines Agency (EMA) granted marketing authorization for its investigational gene therapy valoctocogene roxaparvovec for adults with severe hemophilia A.

July 2020: Gene therapy company Spark Therapeutics presented at the International Society of Thrombosis and Hemostasis (ISTH) 2020.

Hemophilia Treatment Market Segmentation

Hemophilia Treatment Type Outlook

• Hemophilia A


• Hemophilia B


• Hemophilia C

Hemophilia Treatment End-Use Outlook

• Hospital pharmacy


• Retail pharmacy


• Others

Hemophilia Treatment Regional Outlook

• 
  

  North America

  
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  

  Europe

  
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  

  Asia-Pacific

  
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America

    
    
  
  
  
  

• 
  

  Asia-Pacific

  
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America